Showing results (711-720 of 944) with videos related to

Sort By:
Pageof 95
Plant Physiology|May 23, 1998
Biological activity of reducing-end-derivatized oligogalacturonides in tobacco tissue culturesM D Spiro, B L Ridley, S Eberhard, et al.
The Journal of Biological Chemistry|December 20, 2021
Signaling metabolite L-2-hydroxyglutarate activates the transcription factor HIF-1α in lipopolysaccharide-activated macrophagesNiamh C Williams, Dylan G Ryan, Ana S H Costa, et al.
Journal of Pediatric Surgery|June 8, 1999
Congenital hyperinsulinism and the surgeon: lessons learned over 35 yearsH N Lovvorn, M L Nance, R J Ferry, et al.
The EMBO Journal|February 15, 1994
Calcineurin acts in synergy with PMA to inactivate I kappa B/MAD3, an inhibitor of NF-kappa BB Frantz, E C Nordby, G Bren, et al.
Anti-Cancer Drugs|August 13, 2005
Usnic acid: a non-genotoxic compound with anti-cancer propertiesMargareth Mayer, Mary A O'Neill, Karen E Murray, et al.
Journal of Diabetes|December 2, 2015
A randomized clinical trial evaluating the safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic controlRobert G Moses, Elizabeth Round, Yue Shentu, et al.
Toxicologic Pathology|June 15, 1999
Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibodyA M Ryan, D B Eppler, K E Hagler, et al.
BMC Endocrine Disorders|November 8, 2017
A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metforminSeung-Hwan Lee, Ira Gantz, Elizabeth Round, et al.
Diabetes, Obesity & Metabolism|January 29, 2021
A randomized, placebo-controlled study to evaluate the efficacy and safety of adding omarigliptin to insulin therapy in Japanese patients with type 2 diabetes and inadequate glycaemic controlTakashi Kadowaki, Yutaka Seino, Kohei Kaku, et al.
British Journal of Cancer|January 8, 2004
Increased risk of malignant progression in benign proliferating breast lesions defined by expression of heat shock protein 27P A O'Neill, A M Shaaban, C R West, et al.
Pageof 95